These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38262797)

  • 1. Mirikizumab (Omvoh™) for ulcerative colitis.
    Hammerhøj A; Boye TL; Langholz E; Nielsen OH
    Trends Pharmacol Sci; 2024 Mar; 45(3):281-282. PubMed ID: 38262797
    [No Abstract]   [Full Text] [Related]  

  • 2. Mirikizumab for the Management of Ulcerative Colitis.
    Venkateswaran N
    Gastroenterology; 2024 Apr; 166(4):710. PubMed ID: 37926125
    [No Abstract]   [Full Text] [Related]  

  • 3. Mirikizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mirikizumab for ulcerative colitis].
    Sievers LK; Schreiber S; Nitschmann S
    Inn Med (Heidelb); 2023 Dec; 64(12):1230-1231. PubMed ID: 37847261
    [No Abstract]   [Full Text] [Related]  

  • 9. Mirikizumab (Omvoh) for ulcerative colitis.
    Med Lett Drugs Ther; 2024 Mar; 66(1698):46-47. PubMed ID: 38466213
    [No Abstract]   [Full Text] [Related]  

  • 10. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
    Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
    Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of interleukin 13 blockade in ulcerative colitis.
    Tilg H; Kaser A
    Gut; 2015 Jun; 64(6):857-8. PubMed ID: 25804632
    [No Abstract]   [Full Text] [Related]  

  • 15. Etrolizumab in moderate-to-severe ulcerative colitis.
    Armuzzi A; Felice C
    Lancet; 2014 Jul; 384(9940):285-6. PubMed ID: 24814088
    [No Abstract]   [Full Text] [Related]  

  • 16. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.
    Fiorino G; Danese S
    Gastroenterology; 2014 Dec; 147(6):1433-5. PubMed ID: 25457851
    [No Abstract]   [Full Text] [Related]  

  • 17. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
    Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
    Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
    [No Abstract]   [Full Text] [Related]  

  • 18. [The management of ulcerative colitis in remission stage and the strategies for colorectal cancer surveillance in ulcerative colitis].
    Takahashi S; Kinouchi Y; Endo K; Shiga H; Shimosegawa T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Dec; 108(12):1983-95. PubMed ID: 22139485
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
    Zoet ID; de Boer NK; de Meij TG
    J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Warner B; Harris AW
    Gastroenterology; 2012 Jul; 143(1):e42; author reply e42. PubMed ID: 22634354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.